董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony F. Holler | 男 | Director, Chairman of the Board | -- | 未披露 | 未持股 | 2017-03-30 |
| Todd Patrick | 男 | Director | -- | 未披露 | 未持股 | 2017-03-30 |
| Ian Webb | 男 | Director | -- | 未披露 | 未持股 | 2017-03-30 |
| Edward Wright | 男 | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2017-03-30 |
| David Johnson | 男 | Director | 60 | 未披露 | 未持股 | 2017-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward Wright | 男 | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2017-03-30 |
| Richard Bear | 男 | Chief Financial Officer | -- | 未披露 | 未持股 | 2017-03-30 |
| Jay Kreger | 男 | President, CRH Anesthesia | -- | 未披露 | 未持股 | 2017-03-30 |
| Richard Bear | 男 | Chief Financial Officer | 61 | 未披露 | 未持股 | 2017-03-30 |
董事简历
中英对照 | 中文 | 英文- Anthony F. Holler
-
Anthony F. Holler，2005年12月21日被任命为本公司董事和董事会主席。Holler博士现在是 ID Biomedical Corporation "ID Biomedical"的创始人之一，并且在 ID Biomedical担任大量执行职位，包括首席执行官和董事。Holler博士从ID Biomedical 辞职，正值 ID Biomedical被 GlaxoSmithKline收购完成之际。创立ID Biomedical 之前，Holler博士担任the University of British Columbia高校医院急救医生。
Anthony F. Holler has served as one of our directors since December 2005. Dr. Holler was one of the original founders of ID Biomedical Corporation in 1991 and was a member of its Board of Directors since inception. He held a number of executive positions with ID Biomedical, including Chief Executive Officer, until the company was acquired by GlaxoSmithKline in December 2005. Prior to founding ID Biomedical, Dr. Holler served as an emergency physician at University Hospital at the University of British Columbia. He is a member of the British Columbia College of Physicians and Surgeons. Dr. Holler holds a Bachelor of Science degree and a medical degree from the University of British Columbia. - Anthony F. Holler，2005年12月21日被任命为本公司董事和董事会主席。Holler博士现在是 ID Biomedical Corporation "ID Biomedical"的创始人之一，并且在 ID Biomedical担任大量执行职位，包括首席执行官和董事。Holler博士从ID Biomedical 辞职，正值 ID Biomedical被 GlaxoSmithKline收购完成之际。创立ID Biomedical 之前，Holler博士担任the University of British Columbia高校医院急救医生。
- Anthony F. Holler has served as one of our directors since December 2005. Dr. Holler was one of the original founders of ID Biomedical Corporation in 1991 and was a member of its Board of Directors since inception. He held a number of executive positions with ID Biomedical, including Chief Executive Officer, until the company was acquired by GlaxoSmithKline in December 2005. Prior to founding ID Biomedical, Dr. Holler served as an emergency physician at University Hospital at the University of British Columbia. He is a member of the British Columbia College of Physicians and Surgeons. Dr. Holler holds a Bachelor of Science degree and a medical degree from the University of British Columbia.
- Todd Patrick
-
Todd Patrick于2006年5月25日被任命为公司董事。Patrick自2010年11月起担任C3 Jian, Inc.（一家私营生物技术公司，位于加利佛尼亚州洛杉矶）总裁和首席执行官。加入C3 Jian, Inc.之前，Patrick从1994年7月到2006年1月在ID Biomedical担任总裁，辞职时正值ID Biomedical完成对GlaxoSmithKline的收购。
Todd Patrick is the President and Chief Executive Officer of C3J Therapeutics, Inc., a clinical stage biotechnology company based in Los Angeles, California. Prior to joining C3J, Mr. Patrick was the President and Chief Operating Officer of ID Biomedical Corporation. Mr. Patrick was with ID Biomedical from 1994 until 2005 when the company was acquired by GlaxoSmithKline. Prior to ID Biomedical, Mr. Patrick was the Director of the Office of Intellectual Property Administration at the University of California, Los Angeles UCLA, where he was responsible for the patenting and licensing of intellectual property arising out of UCLA. Mr. Patrick holds a B.A. (Economics) from the University of Washington and a Master’s in Business Administration from Washington State University. Mr. Patrick has been a director of the Company since May 2006. - Todd Patrick于2006年5月25日被任命为公司董事。Patrick自2010年11月起担任C3 Jian, Inc.（一家私营生物技术公司，位于加利佛尼亚州洛杉矶）总裁和首席执行官。加入C3 Jian, Inc.之前，Patrick从1994年7月到2006年1月在ID Biomedical担任总裁，辞职时正值ID Biomedical完成对GlaxoSmithKline的收购。
- Todd Patrick is the President and Chief Executive Officer of C3J Therapeutics, Inc., a clinical stage biotechnology company based in Los Angeles, California. Prior to joining C3J, Mr. Patrick was the President and Chief Operating Officer of ID Biomedical Corporation. Mr. Patrick was with ID Biomedical from 1994 until 2005 when the company was acquired by GlaxoSmithKline. Prior to ID Biomedical, Mr. Patrick was the Director of the Office of Intellectual Property Administration at the University of California, Los Angeles UCLA, where he was responsible for the patenting and licensing of intellectual property arising out of UCLA. Mr. Patrick holds a B.A. (Economics) from the University of Washington and a Master’s in Business Administration from Washington State University. Mr. Patrick has been a director of the Company since May 2006.
- Ian Webb
-
Ian Webb于2006年5月25日被任命为本公司董事会成员。Webb先生自2010年12月31日起，一直是退休状态。在此之前，他是Borden Ladner Gervais LLP律师事务所的合伙人。 他的执业重点是公司法和证券法，侧重于上市公司的法律要求。
Ian Webb has been a director of the Company since May 2006. He was admitted to the British Columbia bar in 1982 after graduating from Osgoode Hall Law School at York University with a Bachelor of Laws in 1981. Prior to that, Mr. Webb received a Master of Science in Theoretical Physics from the University of Saskatchewan in 1976. Mr. Webb practiced in the areas of corporate and securities law with an emphasis on the legal requirements of public companies. He is a retired partner of the law firm Borden Ladner Gervais LLP. - Ian Webb于2006年5月25日被任命为本公司董事会成员。Webb先生自2010年12月31日起，一直是退休状态。在此之前，他是Borden Ladner Gervais LLP律师事务所的合伙人。 他的执业重点是公司法和证券法，侧重于上市公司的法律要求。
- Ian Webb has been a director of the Company since May 2006. He was admitted to the British Columbia bar in 1982 after graduating from Osgoode Hall Law School at York University with a Bachelor of Laws in 1981. Prior to that, Mr. Webb received a Master of Science in Theoretical Physics from the University of Saskatchewan in 1976. Mr. Webb practiced in the areas of corporate and securities law with an emphasis on the legal requirements of public companies. He is a retired partner of the law firm Borden Ladner Gervais LLP.
- Edward Wright
-
Edward Wright成为首席执行官，并于2006年9月18日被任命为本公司董事会成员。Wright先生从Cartier North America加盟本公司，自2005年起担任北美零售业务的执行副总裁。 在此之前，Wright先生自2001年起担任Baume & Mercier的总裁。在Cartier，Wright先生负责整个北美零售部门的开发和运营，包括实施战略目标，零售发展的监管，确保部门成功的成果。
Edward Wright became CEO and director of the Company in September of 2006. Prior to joining CRH he gained extensive management experience in global luxury brands at Richemont, the holding company for some of the world’s leading luxury goods. As President of Baume & Mercier first, and then as Executive Vice-President of North America Retail for Cartier, Mr. Wright developed an ability for building solid relationships with customers and business partners alike. Upon arriving at CRH, Mr. Wright was tasked with maximizing the value of the CRH O’Regan System. He quickly determined that CRH needed to transition from a retail model to a wholesale model and by introducing it to the GI community in the United States, he created a paradigm shift for GIs by extending their continuum of care for patients. To maximize the value of CRH, Mr. Wright leveraged our relationships with the GI community leading to the launch of CRH Anesthesia Management, a business focused on providing GI anesthesia services to ASCs across the United States. CRH Anesthesia Management is now the primary driver of the Company’s revenue. Under Mr. Wright’s management CRH has become a profitable company with strong cash flow generation and access to North American capital markets to fund the Company’s long-term growth strategy. - Edward Wright成为首席执行官，并于2006年9月18日被任命为本公司董事会成员。Wright先生从Cartier North America加盟本公司，自2005年起担任北美零售业务的执行副总裁。 在此之前，Wright先生自2001年起担任Baume & Mercier的总裁。在Cartier，Wright先生负责整个北美零售部门的开发和运营，包括实施战略目标，零售发展的监管，确保部门成功的成果。
- Edward Wright became CEO and director of the Company in September of 2006. Prior to joining CRH he gained extensive management experience in global luxury brands at Richemont, the holding company for some of the world’s leading luxury goods. As President of Baume & Mercier first, and then as Executive Vice-President of North America Retail for Cartier, Mr. Wright developed an ability for building solid relationships with customers and business partners alike. Upon arriving at CRH, Mr. Wright was tasked with maximizing the value of the CRH O’Regan System. He quickly determined that CRH needed to transition from a retail model to a wholesale model and by introducing it to the GI community in the United States, he created a paradigm shift for GIs by extending their continuum of care for patients. To maximize the value of CRH, Mr. Wright leveraged our relationships with the GI community leading to the launch of CRH Anesthesia Management, a business focused on providing GI anesthesia services to ASCs across the United States. CRH Anesthesia Management is now the primary driver of the Company’s revenue. Under Mr. Wright’s management CRH has become a profitable company with strong cash flow generation and access to North American capital markets to fund the Company’s long-term growth strategy.
- David Johnson
-
David Johnson， 自2004年11月起担任JLL的执行副总裁和全球首席信息官。1999年至2004年，他是JLL在美洲业务分部的首席信息官。他于1997年7月加入LaSalle Partners（JLL的前身公司），担任管理服务组的技术负责人。在加入LaSalle Partners之前， 1993年至1997年，Johnson先生是PricewaterhouseCoopers在芝加哥和纽约的房地产运营和系统组实践领导；1990年至1993年担任Dreyfus Realty Advisors的投资组合表现经理和在纽约城的技术负责人。在加入Dreyfus之前，他在商业银行业担任过多个职位。Johnson先生获得了Ithaca College的数学和经济学学士学位，和Pace University的金融学和经济学工商管理硕士学位。
David Johnson has been a director of the Company since June of 2010 and is a partner of Gastrointestinal and Liver Specialists of Tidewater PLLC in Norfolk, VA since 1989. Dr. Johnson was one of the founding members of CRH's Scientific Advisory Board. He is Board-certified in Internal Medicine and Gastroenterology and is a past President, as well as a Master of the American College of Gastroenterology. Dr. Johnson currently serves as Professor of Medicine, Chief of Gastroenterology, in Eastern Virginia Medical School. He has authored more than 600 papers in the field of gastroenterology. - David Johnson， 自2004年11月起担任JLL的执行副总裁和全球首席信息官。1999年至2004年，他是JLL在美洲业务分部的首席信息官。他于1997年7月加入LaSalle Partners（JLL的前身公司），担任管理服务组的技术负责人。在加入LaSalle Partners之前， 1993年至1997年，Johnson先生是PricewaterhouseCoopers在芝加哥和纽约的房地产运营和系统组实践领导；1990年至1993年担任Dreyfus Realty Advisors的投资组合表现经理和在纽约城的技术负责人。在加入Dreyfus之前，他在商业银行业担任过多个职位。Johnson先生获得了Ithaca College的数学和经济学学士学位，和Pace University的金融学和经济学工商管理硕士学位。
- David Johnson has been a director of the Company since June of 2010 and is a partner of Gastrointestinal and Liver Specialists of Tidewater PLLC in Norfolk, VA since 1989. Dr. Johnson was one of the founding members of CRH's Scientific Advisory Board. He is Board-certified in Internal Medicine and Gastroenterology and is a past President, as well as a Master of the American College of Gastroenterology. Dr. Johnson currently serves as Professor of Medicine, Chief of Gastroenterology, in Eastern Virginia Medical School. He has authored more than 600 papers in the field of gastroenterology.
高管简历
中英对照 | 中文 | 英文- Edward Wright
Edward Wright成为首席执行官，并于2006年9月18日被任命为本公司董事会成员。Wright先生从Cartier North America加盟本公司，自2005年起担任北美零售业务的执行副总裁。 在此之前，Wright先生自2001年起担任Baume & Mercier的总裁。在Cartier，Wright先生负责整个北美零售部门的开发和运营，包括实施战略目标，零售发展的监管，确保部门成功的成果。
Edward Wright became CEO and director of the Company in September of 2006. Prior to joining CRH he gained extensive management experience in global luxury brands at Richemont, the holding company for some of the world’s leading luxury goods. As President of Baume & Mercier first, and then as Executive Vice-President of North America Retail for Cartier, Mr. Wright developed an ability for building solid relationships with customers and business partners alike. Upon arriving at CRH, Mr. Wright was tasked with maximizing the value of the CRH O’Regan System. He quickly determined that CRH needed to transition from a retail model to a wholesale model and by introducing it to the GI community in the United States, he created a paradigm shift for GIs by extending their continuum of care for patients. To maximize the value of CRH, Mr. Wright leveraged our relationships with the GI community leading to the launch of CRH Anesthesia Management, a business focused on providing GI anesthesia services to ASCs across the United States. CRH Anesthesia Management is now the primary driver of the Company’s revenue. Under Mr. Wright’s management CRH has become a profitable company with strong cash flow generation and access to North American capital markets to fund the Company’s long-term growth strategy.- Edward Wright成为首席执行官，并于2006年9月18日被任命为本公司董事会成员。Wright先生从Cartier North America加盟本公司，自2005年起担任北美零售业务的执行副总裁。 在此之前，Wright先生自2001年起担任Baume & Mercier的总裁。在Cartier，Wright先生负责整个北美零售部门的开发和运营，包括实施战略目标，零售发展的监管，确保部门成功的成果。
- Edward Wright became CEO and director of the Company in September of 2006. Prior to joining CRH he gained extensive management experience in global luxury brands at Richemont, the holding company for some of the world’s leading luxury goods. As President of Baume & Mercier first, and then as Executive Vice-President of North America Retail for Cartier, Mr. Wright developed an ability for building solid relationships with customers and business partners alike. Upon arriving at CRH, Mr. Wright was tasked with maximizing the value of the CRH O’Regan System. He quickly determined that CRH needed to transition from a retail model to a wholesale model and by introducing it to the GI community in the United States, he created a paradigm shift for GIs by extending their continuum of care for patients. To maximize the value of CRH, Mr. Wright leveraged our relationships with the GI community leading to the launch of CRH Anesthesia Management, a business focused on providing GI anesthesia services to ASCs across the United States. CRH Anesthesia Management is now the primary driver of the Company’s revenue. Under Mr. Wright’s management CRH has become a profitable company with strong cash flow generation and access to North American capital markets to fund the Company’s long-term growth strategy.
- Richard Bear
Richard Bear自2006年3月以来一直担任该公司的高级管理人员。任职CRH公司之前，他曾任职ID Biomedical Corporation，最初担任财务Vice President，随后担任首席财务官。自加入CRH以来，Bear先生计划并执行了我们所有的金融交易，包括资本私募，债务发行和重组，与美国和加拿大金融机构建立和扩展我们现有的信贷额度，以及在纽约证券交易所上市我们的普通股MKT。自2014年12月起，Bear先生还负责CRH麻醉管理公司（CRH Ansense Management）收购到我们组织的谈判和融资，以及会计和财务整合。Bear先生拥有华盛顿大学（University of Washington）的工商管理学位，并获得注册会计师注册会计师称号。
Richard Bear has been an officer of the Company since March of 2006. Prior to CRH, he worked at ID Biomedical Corporation, first as Vice President of Finance and then as Chief Financial Officer. Since joining CRH, Mr. Bear has planned and executed all of our financial transactions including capital private placement, debt issuance and restructuring, establishment and extension of our existing credit facility with U.S. and Canadian financial institutions, and listing of our common shares on the NYSE MKT. Since December of 2014 Mr. Bear has also been in charge of the negotiation and financing, as well as the accounting and financial integration of CRH Anesthesia Management’s acquisitions into our organization. Mr. Bear has a degree in Business Administration from the University of Washington and has received a Certified Public Accountant CPA designation.- Richard Bear自2006年3月以来一直担任该公司的高级管理人员。任职CRH公司之前，他曾任职ID Biomedical Corporation，最初担任财务Vice President，随后担任首席财务官。自加入CRH以来，Bear先生计划并执行了我们所有的金融交易，包括资本私募，债务发行和重组，与美国和加拿大金融机构建立和扩展我们现有的信贷额度，以及在纽约证券交易所上市我们的普通股MKT。自2014年12月起，Bear先生还负责CRH麻醉管理公司（CRH Ansense Management）收购到我们组织的谈判和融资，以及会计和财务整合。Bear先生拥有华盛顿大学（University of Washington）的工商管理学位，并获得注册会计师注册会计师称号。
- Richard Bear has been an officer of the Company since March of 2006. Prior to CRH, he worked at ID Biomedical Corporation, first as Vice President of Finance and then as Chief Financial Officer. Since joining CRH, Mr. Bear has planned and executed all of our financial transactions including capital private placement, debt issuance and restructuring, establishment and extension of our existing credit facility with U.S. and Canadian financial institutions, and listing of our common shares on the NYSE MKT. Since December of 2014 Mr. Bear has also been in charge of the negotiation and financing, as well as the accounting and financial integration of CRH Anesthesia Management’s acquisitions into our organization. Mr. Bear has a degree in Business Administration from the University of Washington and has received a Certified Public Accountant CPA designation.
- Jay Kreger
Jay Kreger拥有超过25年的多元化经验，专注于业务开发和运营。加入CRH公司之前，他曾担任Hospital Corporation of America的流动外科部门的开发Vice President。Kreger先生在密歇根州立大学（Michigan State University）获得金融学学士学位，并在韦恩州立大学（Wayne State University）获得工商管理硕士学位。
Jay Kreger has over 25 years of diversified experience, focusing on business development and operations. Prior to joining CRH, he held the role of Vice President of Development for the Ambulatory Surgery Division at Hospital Corporation of America. Mr. Kreger received a BA in Finance at Michigan State University and a MBA at Wayne State University.- Jay Kreger拥有超过25年的多元化经验，专注于业务开发和运营。加入CRH公司之前，他曾担任Hospital Corporation of America的流动外科部门的开发Vice President。Kreger先生在密歇根州立大学（Michigan State University）获得金融学学士学位，并在韦恩州立大学（Wayne State University）获得工商管理硕士学位。
- Jay Kreger has over 25 years of diversified experience, focusing on business development and operations. Prior to joining CRH, he held the role of Vice President of Development for the Ambulatory Surgery Division at Hospital Corporation of America. Mr. Kreger received a BA in Finance at Michigan State University and a MBA at Wayne State University.
- Richard Bear
自2019年5月合并完成以来，Richard Bear一直担任董事会成员。他是CRH Medical Corporation（NYSE American:CRHM）的首席财务官，该公司是一家医疗服务公司（“；CRH”；），自2006年以来一直担任CRH的高级管理人员。在加入CRH之前，Bear先生从2002年到2005年在ID Biomedical Corporation担任首席财务官，2005年该公司被GlaxoSmithKline plc收购。在id biomedical corporation任职期间，他参与了公开募股、房地产售后回租交易和其他融资活动，创造了超过3.5亿美元的收入，还参与了该公司以15亿新元被GlaxoSmithKline plc收购的交易。在加入ID Biomedical Corporation之前，Bear先生在电信行业工作了15年，担任McCaw Cellular Communications，AT&T Wireless和XO Communications的会计，财务和高级管理职位。Bear先生曾在私人和上市公司的董事会任职，包括在某些情况下担任审计委员会主席。他也一直活跃在几个慈善组织的董事会。
Richard Bear has served as a member of the Board since the consummation of the Merger in May 2019. He is the Chief Financial Officer of CRH Medical Corporation NYSE American: CRHM, a medical services business (“CRH”), and has served as an officer of CRH since 2006. Prior to joining CRH, Mr. Bear worked at ID Biomedical Corporation as Chief Financial Officer from 2002 until 2005 when the company was acquired by GlaxoSmithKline plc. During his time at ID Biomedical Corporation, he worked on public offerings, real-estate sale/leaseback transactions and other financing activities generating in excess of $350 million, as well as the company’s $1.5 billion acquisition by GlaxoSmithKline plc. Before joining ID Biomedical Corporation, Mr. Bear spent 15 years working in the telecommunications industry in accounting, financial, and senior management roles for McCaw Cellular Communications, AT&T Wireless and XO Communications. Mr. Bear has served on the boards of directors of private and public companies, including in some instances as audit committee chairperson. He has also been active on the boards of several charitable organizations.- 自2019年5月合并完成以来，Richard Bear一直担任董事会成员。他是CRH Medical Corporation（NYSE American:CRHM）的首席财务官，该公司是一家医疗服务公司（“；CRH”；），自2006年以来一直担任CRH的高级管理人员。在加入CRH之前，Bear先生从2002年到2005年在ID Biomedical Corporation担任首席财务官，2005年该公司被GlaxoSmithKline plc收购。在id biomedical corporation任职期间，他参与了公开募股、房地产售后回租交易和其他融资活动，创造了超过3.5亿美元的收入，还参与了该公司以15亿新元被GlaxoSmithKline plc收购的交易。在加入ID Biomedical Corporation之前，Bear先生在电信行业工作了15年，担任McCaw Cellular Communications，AT&T Wireless和XO Communications的会计，财务和高级管理职位。Bear先生曾在私人和上市公司的董事会任职，包括在某些情况下担任审计委员会主席。他也一直活跃在几个慈善组织的董事会。
- Richard Bear has served as a member of the Board since the consummation of the Merger in May 2019. He is the Chief Financial Officer of CRH Medical Corporation NYSE American: CRHM, a medical services business (“CRH”), and has served as an officer of CRH since 2006. Prior to joining CRH, Mr. Bear worked at ID Biomedical Corporation as Chief Financial Officer from 2002 until 2005 when the company was acquired by GlaxoSmithKline plc. During his time at ID Biomedical Corporation, he worked on public offerings, real-estate sale/leaseback transactions and other financing activities generating in excess of $350 million, as well as the company’s $1.5 billion acquisition by GlaxoSmithKline plc. Before joining ID Biomedical Corporation, Mr. Bear spent 15 years working in the telecommunications industry in accounting, financial, and senior management roles for McCaw Cellular Communications, AT&T Wireless and XO Communications. Mr. Bear has served on the boards of directors of private and public companies, including in some instances as audit committee chairperson. He has also been active on the boards of several charitable organizations.